Back to results

[Tc-99m]-RPI-087 as an Imaging Marker in Osteoarthritis of the Knee Compared to Healthy Volunteers

Primary Purpose

Healthy, Osteo Arthritis Knee

Status

Unknown status

Phase

Phase 1

Locations

Canada

Study Type

Interventional

Intervention

[Tc-99m]-RPI-T-087 Injection

About this trial

This is an interventional diagnostic trial for Healthy

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria :

All subjects must be able to read and speak in English and capable of giving signed informed consent.
Female subjects must either, not be of reproductive potential, or not be pregnant and be willing to comply with appropriate family planning methods as specified in the protocol.
Male subjects must either, not be of reproductive potential or be willing to comply with appropriate family planning methods as specified in the protocol.

Subjects with Knee Osteoarthritis (KOA)

Age ≥ 40 to ≤ 70 years, at the time of signing the informed consent
Have chronic pain due to OA of at least one knee identifiable as the target knee as their primary pain condition and some degree of pain every day from this condition.

For Healthy Volunteers:

Age ≥ 18 to ≤ 35 years, at the time of signing the informed consent.
No history of knee pain or known knee pathology confirmed by knee radiographs, obtained within the last year.

Exclusion Criteria:

Chronic pain conditions other than OA of the knee (KOA) as their predominant pain condition
Cannot or will not agree to stop: all topical, oral and parenteral non-steroidal anti-inflammatory drugs (NSAIDs) for at least 48 hours before administration of the IP; stop turmeric and curcumin (supplements and dietary sources) for at least 48 hours before administration of the IP; avoid all exercise from at least 24 hours before administration of the IP up to the end of the last applicable imaging session.
Systemic (including inhaled) and oral corticosteroid use currently or within 6 weeks prior to Visit 1.
Surgical interventions of either knee or any other major surgery within the previous 6 months.
Receipt of intra-articular corticosteroid injections within the previous 6 weeks prior to Visit 1 in the target knee or within the previous 2 weeks prior to Visit 1 in any other joint.
Use of any other investigational medication or devices within 30 days prior to Visit 1.
Orthopedic or prosthetic appliance in either knee which may confound scan interpretation.
Screening ECG or laboratory assessments showing clinically significant abnormalities
Refusal or inability to tolerate the scanning procedures
Allergies to or cannot tolerate NSAIDs, the investigational product or sulfa drugs
History of bleeding disorders or history of documented gastrointestinal ulcer disease.
Received significant ionizing radiation exposure, in the last 12 months or undergoing occupational monitoring for radiation exposure.
Allergies or sensitivity to any component of the investigational product. Subjects taking disulfiram (Antabuse) should be excluded from this study.
History of alcohol or substance abuse
Any medical condition or disease that in the opinion of the investigator makes the subject unsuitable to participate in this study.

Sites / Locations

St. Joseph's Healthcare HamiltonRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Arm Label

Healthy Volunteers

Osteo Arthritis of the knee

Arm Description

Healthy volunteers will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety, knee image evaluation, and radioactivity biodistribution and dosimetry.

Subjects with knee osteoarthritis will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety and knee image evaluation.

Outcomes

Primary Outcome Measures

Incidence of treatment emergent adverse events

The incidence of adverse events, including injection site reactions, clinically significant changes in clinical laboratory parameters (blood and urine), ECG's and vital signs, will be summarized over time to assess safety and tolerability.

Secondary Outcome Measures

Uptake over time

Quantitative standard uptake values (SUV) for T-087 will be determined for the knees of subjects with KOA and HVs, and comparing uptake in the target knee of OA subjects with the uptake in the knees of the HVs.

Image quality

A visual assessment using a scoring system will be used to assess the SPECT/CT images quality in subjects with KOA. Image quality scales of 1 to 3, with 1 as unacceptable (non-interpretable quality), 2 as adequate quality for interpretation and 3 as excellent quality (no issues) of the target knee will be descriptively summarized by time point and subject group.

Dosimetry

Whole body planar imaging of healthy volunteers will be used to evaluate the biodistribution of [Tc-99m]-RPI-T-087 Injection to estimate dosimetry. Whole body scintigraphic images will be quantified as to fractional activity (IA) in various visceral organs (e.g., liver, lungs, heart) as well as routes of excretion, total body and knees. The data describing the uptake, retention and clearance in these tissues will characterize the biodistribution and biokinetics of the IP. These data also serve as the foundation for radiation dose estimates for the IP.

Full Information

NCT ID

NCT03503825

First Posted

April 6, 2018

Last Updated

January 11, 2019

Sponsor

Reiley Pharmaceuticals Inc.

1. Study Identification

Unique Protocol Identification Number

NCT03503825

Brief Title

[Tc-99m]-RPI-087 as an Imaging Marker in Osteoarthritis of the Knee Compared to Healthy Volunteers

Official Title

A Phase 1, Open-label, Non-Randomized Study to Evaluate the Safety and Tolerability of [Tc-99m]-RPI T-087 Injection as an Imaging Marker for COX-2 in Subjects With Osteoarthritis of the Knee Compared to Healthy Volunteers

Study Type

Interventional

2. Study Status

Record Verification Date

January 2019

Overall Recruitment Status

Unknown status

Study Start Date

August 16, 2018 (Actual)

Primary Completion Date

May 31, 2019 (Anticipated)

Study Completion Date

June 30, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Reiley Pharmaceuticals Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Product Manufactured in and Exported from the U.S.

Data Monitoring Committee

5. Study Description

Brief Summary

The main purpose of this study is to test the safety and tolerability of T-087. The study will enroll 6 healthy volunteers (HVs) and 6-18 subjects with KOA. All eligible subjects will receive an intravenous injection of the radioactive investigational product (ip) (T-087), followed by SPECT/CT imaging of the knees and blood tests and clinical assessments for safety monitoring. Healthy volunteers will also have their whole body imaged and have extra blood drawn to determine where T-087 goes in the body. These additional procedures will be done on the same day as the ip administration, and repeated the following day. All subjects will have a final follow-up phone call within 2- 3 business days following the ip administration.

Detailed Description

This is a Phase 1, non-randomized, open label, single centre clinical trial. 6 healthy volunteers (3 male and 3 female,4 study visits) and 6-18 subjects with Osteoarthritis of the knee (3 study visits) will be enrolled. At visit 2, all subjects will have knee pain assessed, using a visual analogue scale, prior to receiving a single, 555 MBq (15 mCi)+/-10% dose of [Tc-99m)-RPI-T-087 injection. Knees will be imaged with a SPECT/CT camera at specified time-points post injection. Safety monitoring will include vital signs, ECG, clinical laboratory tests (serum biochemistry, haematology, urinalysis) and adverse event monitoring. Additionally, HVs will have whole body planar imaging and blood sampling conducted at Visit 2 and 3 to evaluate bio-distribution, estimate dosimetry and measure clearance of total activity over time in blood samples. A final follow-up visit will be conducted by phone interview. Once 6 HVs and 6 KOA participants have completed the study, a blinded assessment of the image data will be conducted to determine whether any more KOA subjects should be imaged.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Healthy, Osteo Arthritis Knee

7. Study Design

Primary Purpose

Diagnostic

Study Phase

Phase 1

Interventional Study Model

Parallel Assignment

Model Description

This is a Phase 1, non-randomized, open-label, single-centre clinical trial. A total of 12 to 24 subjects will be enrolled: 6 Healthy volunteers (HV) (3 males and 3 females) 6 - 18 subjects with osteoarthritis of the knee (KOA) Once 6 HVs and 6 KOA subjects (to be enrolled concurrently) have completed the study, image data will be assessed to determine whether any more KOA subjects should be imaged.

Masking

None (Open Label)

Allocation

Non-Randomized

Enrollment

24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

Healthy Volunteers

Arm Type

Experimental

Arm Description

Arm Title

Osteo Arthritis of the knee

Arm Type

Experimental

Arm Description

Subjects with knee osteoarthritis will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety and knee image evaluation.

Intervention Type

Drug

Intervention Name(s)

[Tc-99m]-RPI-T-087 Injection

Other Intervention Name(s)

T-087

Intervention Description

A single intravenous injection of [Tc-99m]-RPI-T-087 followed by SPECT/CT imaging of the knee (all subjects) and whole body planar imaging (Healthy volunteers only)

Primary Outcome Measure Information:

Title

Incidence of treatment emergent adverse events

Description

Time Frame

Up to 3 days post investigative product administration

Secondary Outcome Measure Information:

Title

Uptake over time

Description

Time Frame

Up to 4.5 hours post administration of the investigational product

Title

Image quality

Description

Time Frame

Up to 4.5 hours post administration of the investigational product

Title

Dosimetry

Description

Time Frame

Up to 1 day post administration of the investigational product.

Other Pre-specified Outcome Measures:

Title

Clearance of [Tc-99m]-RPI-T-087

Description

Blood sampling (HVs only) will support the exploratory objective of using radioactivity measurements (if measurable) to assess the clearance of [Tc-99m]-RPI-T-087.

Time Frame

Up to 1 day post administration of the investigational product.

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

70 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria : All subjects must be able to read and speak in English and capable of giving signed informed consent. Female subjects must either, not be of reproductive potential, or not be pregnant and be willing to comply with appropriate family planning methods as specified in the protocol. Male subjects must either, not be of reproductive potential or be willing to comply with appropriate family planning methods as specified in the protocol. Subjects with Knee Osteoarthritis (KOA) Age ≥ 40 to ≤ 70 years, at the time of signing the informed consent Have chronic pain due to OA of at least one knee identifiable as the target knee as their primary pain condition and some degree of pain every day from this condition. For Healthy Volunteers: Age ≥ 18 to ≤ 35 years, at the time of signing the informed consent. No history of knee pain or known knee pathology confirmed by knee radiographs, obtained within the last year. Exclusion Criteria: Chronic pain conditions other than OA of the knee (KOA) as their predominant pain condition Cannot or will not agree to stop: all topical, oral and parenteral non-steroidal anti-inflammatory drugs (NSAIDs) for at least 48 hours before administration of the IP; stop turmeric and curcumin (supplements and dietary sources) for at least 48 hours before administration of the IP; avoid all exercise from at least 24 hours before administration of the IP up to the end of the last applicable imaging session. Systemic (including inhaled) and oral corticosteroid use currently or within 6 weeks prior to Visit 1. Surgical interventions of either knee or any other major surgery within the previous 6 months. Receipt of intra-articular corticosteroid injections within the previous 6 weeks prior to Visit 1 in the target knee or within the previous 2 weeks prior to Visit 1 in any other joint. Use of any other investigational medication or devices within 30 days prior to Visit 1. Orthopedic or prosthetic appliance in either knee which may confound scan interpretation. Screening ECG or laboratory assessments showing clinically significant abnormalities Refusal or inability to tolerate the scanning procedures Allergies to or cannot tolerate NSAIDs, the investigational product or sulfa drugs History of bleeding disorders or history of documented gastrointestinal ulcer disease. Received significant ionizing radiation exposure, in the last 12 months or undergoing occupational monitoring for radiation exposure. Allergies or sensitivity to any component of the investigational product. Subjects taking disulfiram (Antabuse) should be excluded from this study. History of alcohol or substance abuse Any medical condition or disease that in the opinion of the investigator makes the subject unsuitable to participate in this study.

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Janet Crouch, BScc, MRT(N)

Phone

(905) 522-1155

Ext

35019

jcrouch@stjoes.ca

First Name & Middle Initial & Last Name or Official Title & Degree

MaryLou Lawlor, RN

Phone

(905) 522-1155

Ext

33790

mlawlor@stjosham.on.ca

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Karen Gulenchyn, MD

Organizational Affiliation

St. Joseph's Hospital Hamilton

Official's Role

Principal Investigator

Facility Information:

Facility Name

St. Joseph's Healthcare Hamilton

City

Hamilton

State/Province

Ontario

Country

Canada

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Janet Crouch, RTNM

Phone

(905) 522-1155

Ext

35019

First Name & Middle Initial & Last Name & Degree

MaryLou, RN

Phone

(905) 522-1155

Ext

33790

First Name & Middle Initial & Last Name & Degree

Karen Gulenchyn, MD

First Name & Middle Initial & Last Name & Degree

Richard Adachi, MD

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

[Tc-99m]-RPI-087 as an Imaging Marker in Osteoarthritis of the Knee Compared to Healthy Volunteers

We'll reach out to this number within 24 hrs